Neurofibromatosis type 1 and autism spectrum disorder

Pediatrics

Volumn 132, Issue 6, 2013, Pages

  Garg, Shruti ^a   Green, Jonathan ^a   Leadbitter, Kathy ^a   Emsley, Richard ^a   Lehtonen, Annukka ^b   Evans, Gareth ^b,c   Huson, Susan M ^b,c  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Autism; Epidemiology; Neurofibromatosis type 1; Population

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; AUTISM; AUTISM DIAGNOSTIC INTERVIEW REVISED; AUTISM DIAGNOSTIC OBSERVATION SCHEDULE; CHILD; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE REGISTRY; DISEASE SEVERITY; EDUCATIONAL STATUS; FEMALE; HUMAN; INHERITANCE; INTELLIGENCE QUOTIENT; MALE; NEUROFIBROMATOSIS; PARENT; PHENOTYPE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; SOCIAL RESPONSIVENESS SCALE; SOCIAL STATUS; UNITED KINGDOM; YOUNG ADULT; CHI SQUARE DISTRIBUTION; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMPLICATION; PRESCHOOL CHILD; PROSPECTIVE STUDY; PSYCHOLOGIC TEST; REGISTER; STATISTICAL MODEL;

ADOLESCENT; CHI-SQUARE DISTRIBUTION; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; ENGLAND; FEMALE; HUMANS; LOGISTIC MODELS; MALE; NEUROFIBROMATOSIS 1; PREVALENCE; PROSPECTIVE STUDIES; PSYCHOLOGICAL TESTS; REGISTRIES;

EID: 84890771989     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2013-1868     Document Type: Article

References (40)

1. Baird G, Simonoff E, Pickles A, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: The Special Needs and Autism Project (SNAP). Lancet. 2006;368(9531): 210-215
2. Centers for Disease Control and Prevention. Why are autism spectrum disorders increasing? Available at: www.cdc.gov/features/autismprevalence/. Accessed December 4, 2012
3. Miller DT. Genetic testing for autism: Recent advances and clinical implications. Expert Rev Mol Diagn. 2010;10(7):837-840
4. Abrahams BS, Geschwind DH. Advances in autism genetics: on the threshold of a new neurobiology. Nat Rev Genet. 2008;9(5):341- 355
5. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. Am J Med Genet A. 2010;152A(2):327-332
6. National Institutes of Health Consensus Development Conference. Neurofibromatosis. Conference statement. Arch Neurol. 1988;45 (5):575-578
7. Hyman S, Shores A, North K. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Dev Med Child Neurol. 2005;65:1037-1044
8. Hachon C, Iannuzzi S, Chaix Y. Behavioural and cognitive phenotypes in children with neurofibromatosis type 1 (NF1): The link with the neurobiological level. Brain Dev. 2011;33(1):52-61
9. Li W, Cui Y, Kushner SA, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol. 2005;15(21):1961-1967
10. Krab LC, de Goede-Bolder A, Aarsen FK, et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: A randomized controlled trial. JAMA. 2008;300(3):287-294
11. Packer A. RAS pathway, a potentially unifying theory of autism. 2012. Available at: http://sfari.org/news-and-opinion/directorscolumns/2012/. Accessed December 4, 2012
12. Molosh A, Spence J, Federici L, et al. Neural mechanisms underlying selective loss of social learning in Neurofibromatosis type 1 gene (Nf1) deficient mice and its restoration by co-deletion of p21-activated kinase 1 (Pak 1) gene. Paper presented at: Society for Neuroscience Annual Meeting, New Orleans, LA; October 13-17, 2012
13. Gillberg C, Forsell C. Childhood psychosis and neurofibromatosis-ore than a coincidence? J Autism Dev Disord. 1984;14(1): 1-8
14. Fombonne E, Du Mazaubrun C, Cans C, Grandjean H. Autism and associated medical disorders in a French epidemiological survey. J Am Acad Child Adolesc Psychiatry. 1997;36(11):1561-1569
15. Mouridsen SE, Andersen LB, Sörensen SA, Rich B, Isager T. Neurofibromatosis in infantile autism and other types of childhood psychoses. Acta Paedopsychiatr. 1992;55(1):15-18
16. Williams PG, Hersh JH. Brief report: The association of neurofibromatosis type 1 and autism. J Autism Dev Disord. 1998;28 (6):567-571
17. Noll RB, Reiter-Purtill J, Moore BD, et al. Social, emotional, and behavioral functioning of children with NF1. Am J Med Genet A. 2007;143A(19):2261-2273
18. Huijbregts S, Jahja R, De Sonneville L, de Breij S, Swaab-Barneveld H. Social information processing in children and adolescents with neurofibromatosis type 1. Dev Med Child Neurol. 2010;52(7):620-625
19. Walsh KS, Vélez JI, Kardel PG, et al. Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol. 2013;55(2):131- 138
20. Berkson J. Limitations of the application of fourfold table analysis to hospital data. Biometrics. 1946;2(3):47-53
21. Galbaud du Fort G, Newman S, Bland R. Psychiatric comorbidity and treatment seeking: sources of selection bias in the study of clinical populations. J Nerv Ment Dis. 1993;181(8):467-474
22. Garg S, Lehtonen A, Huson SM, et al. Autism and other psychiatric comorbidity in neurofibromatosis type 1: Evidence from a population-based study. Dev Med Child Neurol. 2013;55(2):139-145
23. Evans DG, O'Hara C, Wilding A, et al. Mortality in neurofibromatosis 1: in North West England: An assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet. 2011;19(11):1187-1191
24. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24(5):659-685
25. Lord C, Risi S, Lambrecht L, et al. The autism diagnostic observation schedule-generic: A standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30 (3):205-223
26. Sparrrow S, Cicchetti D, Balla D. Vineland Adaptive Behaviour Scales: Second Edition (Vineland 2), Survey Interview form/Caregiver rating form. Livonia, MN: Pearson Assessments; 2005
27. Wechsler D. The Wechsler Intelligence Scale for Children. 4th ed. London, England: Pearson Assessments; 2004
28. Riccardi V. Neurofibromatosis: Phenotype, Natural History and Pathogenesis. 2nd ed. Baltimore, MD: Johns Hopkins University Press; 1992
29. Noble M, McLennan D, Wilkinson K, Whitworth A, Barnes H, Dibben C. The English Indices of Deprivation 2007. London, England: Department for Communities and Local Government; 2008
30. Lainhart JE, Bigler ED, Bocian M, et al. Head circumference and height in autism: A study by the Collaborative Program of Excellence in Autism. Am J Med Genet A. 2006;140(21):2257-2274
31. Lord C, Petkova E, Hus V, et al. A multisite study of the clinical diagnosis of different autism spectrum disorders. Arch Gen Psychiatry. 2012;69(3):306-313
32. Dunn G, Pickles A, Tansella M, Vázquez-Barquero JL. Two-phase epidemiological surveys in psychiatric research. Br J Psychiatry. 1999;174:95-100
33. Pickles A, Dunn G, Vázquez-Barquero JL. Screening for stratification in two-phase ('two-stage') epidemiological surveys. Stat Methods Med Res. 1995;4(1):73-89
34. Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry. 2008;47(8):921-929
35. Kim SH, Lord C. Combining information from multiple sources for the diagnosis of autism spectrum disorders for toddlers and young preschoolers from 12 to 47 months of age. J Child Psychol Psychiatry. 2012;53(2):143-151
36. Dykens EM. Psychiatric and behavioral disorders in persons with Down syndrome. Ment Retard Dev Disabil Res Rev. 2007;13 (3):272-278
37. Reiss S, Levitan GW, Szyszko J. Emotional disturbance and mental retardation: diagnostic overshadowing. Am J Ment Defic. 1982;86(6):567-574
38. Corbin I, Desachy G, Rauen K, Weiss L. Autism Traits in the RASopathies. Abstract presented at: American Society of Human Genetics Annual Meeting; November 6-12, 2012; San Francisco, CA
39. Rosser T, Yong-Seok L, Enrique SA, Bearden C. MAPK levels as a biomarker of cognitive deficits in neurofibromatosis type 1. Paper presented at: Children's Tumor Foundation Neurofibromatosis Conference; June 9-12, 2012; New Orleans, LA
40. Costa RM, Federov NB, Kogan JH, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 2002;415(6871):526-530